Diagonal Bio

Tomas Hammar, responsible for 20 competition horses and actively participating in both national and international events, sees great value in continuously ensuring the health of those horses through regular testing. At competitions, where horses from different stables gather, there is always a risk that infectious diseases such as respiratory viruses, influenza, and herpes viruses (for example EHV1 and EHV4) are spread. These viruses can spread quickly and affect both the well-being of the horses and their ability to compete.

This pilot test is intended to provide faster and more accurate point-of-care diagnostics, thereby enhancing health outcomes for showjumping horses and ensuring more secure horse competitions. The pilot, which will run for three months, will involve using LAMPlify® on Hunneberga Horse Stable’s horses at every event, both to protect their own horses and to demonstrate the technology to other trainers and horse owners. The study also aims to showcase how LAMPlify® can become a new standard for quick and easy testing within the equestrian sports.

“It’s invaluable for us to be able to test our horses, especially when traveling. Being able to run tests the night before a competition and get results within 10-15 minutes ensures that the horses we’re bringing are healthy. The diagnostic processes we are used to involve waiting days for results, which is challenging in an industry where timing is crucial. That’s why we look forward to test LAMPlify®” - Tomas Hammar, CEO of Hunneberga Horse Stable (Hunneberga Hästgård)

“We're excited that more trainers are now taking notice of LAMPlify®, and that this external validation through Tomas Hammar's pilot study is contributing to the growing interest in our technology. We believe that LAMPlify® can make a significant impact in safeguarding the health of competition horses, and this collaboration is a further crucial step in demonstrating its value in real-world settings. We strongly believe the pilot study will demonstrate the positive impact of using LAMPlify® to reduce the risk of outbreaks and improve animal health within the equine industry" - Karin Wehlin, CEO of Diagonal Bio AB (publ)

This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on October 8, 2024, at 19:00 CET.

For more information, please contact:
Karin Wehlin, CEO
Phone: +46 (0)70305 24 88
E-mail: kw@diagonalbio.com

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se

About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.